Core Viewpoint - OssaNova, a product of Aojing Medical, has received registration certification in Vietnam, which is expected to aid the company's expansion into overseas markets, although the specific impact on performance remains uncertain [1][3]. Company Announcements Summary - Aojing Medical has announced that its artificial bone repair material received registration certification from the Vietnamese Ministry of Health, effective from July 16, 2025, with a permanent validity [3]. - The registration number for the product is 2502543ĐKLH/BYT-HTTB, classified as a Class D (high-risk medical device) [3]. - The OssaNova artificial bone repair material is primarily used for bone defect repair in oral or plastic surgery where there are no contraindications for bone grafting, and it has previously received registration in China and Indonesia [3]. - The company has decided to cancel its fundraising account at Industrial Bank due to adjustments in the implementation subject and location of fundraising projects, with the cancellation date set for July 23, 2025 [2][3]. - The termination of the related four-party regulatory agreement has been communicated to the sponsor institution Huatai United and the sponsoring representative [3].

Fundraising Overview - The company raised a total of RMB 547,666,677.62 through the issuance of 33,333,334 shares at a price of RMB 16.43 per share, with a net amount of RMB 500,816,913.05 after deducting issuance costs [1][2] - The funds were verified by an accounting firm and were deposited into a dedicated bank account [1] Fund Management - The company and its subsidiaries have opened dedicated fundraising accounts at various banks to ensure proper management and usage of the raised funds [2] - Agreements have been signed with banks to regulate the management of these funds [2][3] Account Closure - The company has closed a specific fundraising account at Industrial Bank Co., Ltd. due to adjustments in the project implementation [4] - The closure of this account has led to the termination of the corresponding four-party supervision agreement [4]

证券代码：688613 证券简称：奥精医疗 公告编号：2025-039 奥精医疗科技股份有限公司（以下简称"公司"或"本公司"）为规范公 司募集资金的存放、使用与管理，提高资金使用效率和效益，保护投资者权益，根 据《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》等法 律法规、规范性文件以及相关规定，本公司及子公司北京奥精医疗器械有限责任 公司、山东奥精生物科技有限公司、潍坊奥精健康科技有限公司、嘉兴奥精生 物科技有限公司在商业银行开设了募集资金专项账户，用于项目实施时的募集 资金存放。 1 截至本公告披露日，公司及上述子公司、华泰联合证券有限责任公司（以 下简称"华泰联合"或"保荐机构"）已与招商银行股份有限公司北京分行、兴 业银行股份有限公司北京中关村支行、华夏银行股份有限公司北京分行分别签订 《募集资金三方监管协议》、《募集资金四方监管协议》。 | 开户银行 | 银行账号 | 账户类别 | 账户状态 | | --- | --- | --- | --- | | 兴业银行股份有限公司北京中关 | 321070100100447453 | 募集资金专户 | 本次注销 | | 村支行 | | | ...

Group 1 - Haitong Development reported a net profit of 86.87 million yuan for the first half of 2025, a year-on-year decrease of 64.14% [1] - Haitong Development achieved an operating income of 1.8 billion yuan, a year-on-year increase of 6.74% [1] - Crystal Integrated expects a net profit increase of 39.04% to 108.55% for the first half of 2025, with projected revenue between 5.07 billion yuan and 5.32 billion yuan [1] Group 2 - Aerospace Universe anticipates a net profit increase of 50.59% for the first half of 2025, with a projected net profit of 34.38 million yuan [2] - Aerospace Universe's net profit excluding non-recurring gains is expected to grow by 94.90% [2] Group 3 - Guodian Power reported a total power generation of 206.03 billion kWh for the first half of 2025, a year-on-year decrease of 3.61% [3] - The company's market-based transaction electricity accounted for 91.84% of the total electricity sold [3] Group 4 - Shanghai Pharmaceuticals announced that its tranexamic acid injection has passed the consistency evaluation for generic drugs [5] - The drug is primarily used for treating various bleeding disorders [5] Group 5 - Sanyou Chemical received approval to issue up to 900 million yuan in technology innovation corporate bonds [7] - The bond issuance is valid for 24 months from the date of approval [7] Group 6 - Baiyuntian's BAT4406F injection drug has received approval for clinical trials for additional indications [9] - The drug is a next-generation fully human anti-CD20 antibody [9] Group 7 - Huason Pharmaceutical received three drug re-registration approval notices [10] - The approved drugs include Ganji Bingmei tablets and other formulations [10] Group 8 - Shanying International plans to establish the Zhiyuan Fund with a total scale of 100 million yuan [13] - The fund will primarily invest in product companies related to industrial scenarios [13] Group 9 - Yiqiu Resources announced the sale of two properties in Malaysia for a total of approximately 3.67 million yuan [15] - The sale is part of the company's asset management strategy [15] Group 10 - Guizhou Bailing plans to apply for loans totaling no more than 920 million yuan from multiple banks [16] - The loans will be used to replace maturing loans and supplement working capital [16] Group 11 - Samsung Medical's subsidiary won a transformer procurement contract in Brazil worth approximately 341 million yuan [16] - The contract is part of the company's expansion into international markets [16] Group 12 - Changying Tong expects a net profit increase of 72.12% to 110.33% for the first half of 2025 [17] - The projected revenue is between 173 million yuan and 211 million yuan [17] Group 13 - Canqin Technology anticipates a net profit increase of 50.14% to 61.85% for the first half of 2025 [17] - The expected revenue is between 286 million yuan and 290 million yuan [17] Group 14 - Daya Shengxiang signed a lease agreement with an annual rent of 17 million yuan for a production facility [18] - The lease term is for 3 years and 4 months, including a 4-month rent-free period [18] Group 15 - Zhongzai Zihuan announced the resignation of its general manager due to work adjustments [20] - The company will appoint an interim general manager while searching for a permanent replacement [20] Group 16 - Fuwei Co. received a project notification from a well-known luxury brand for seat development [22] - The total sales amount for the project is expected to reach 4.9 billion yuan [22] Group 17 - Meili Technology's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [26] - The issuance is subject to further approval from regulatory authorities [26] Group 18 - Jinzhik Technology announced a stock suspension due to potential control changes [27] - The suspension is expected to last no more than two trading days [27] Group 19 - Zhongtian Technology plans to distribute a cash dividend of 3 yuan per 10 shares [28] - The dividend distribution date is set for July 25, 2025 [28] Group 20 - Huahai Chengke plans to distribute a cash dividend of 0.2002 yuan per share [30] - The dividend distribution date is set for July 29, 2025 [30] Group 21 - Dasheng Intelligent won a smart transportation project contract worth 122 million yuan [31] - The project involves comprehensive monitoring systems for urban rail transit [31] Group 22 - Dongyue Silicon reported a fire incident affecting production operations [32] - The fire has been controlled, but the extent of damage is still being assessed [32] Group 23 - Shaanxi Guotou A reported a net profit of 726 million yuan for the first half of 2025, a year-on-year increase of 5.74% [35] - The company's operating income decreased by 2.95% [35] Group 24 - Yibo Technology announced a plan to reduce shareholding by up to 3% [37] - The reduction is due to the shareholder's funding needs [37] Group 25 - Xiling Information announced a stock suspension due to potential control changes [39] - The suspension is expected to last no more than two trading days [39] Group 26 - Tianli Lithium Energy plans to reduce shareholding by 4.55% through block trading [40] - The reduction is due to the fund's operational timeline nearing its end [40] Group 27 - Sihui Fushi announced plans for a combined shareholding reduction of up to 3% [42] - The reduction is due to the shareholders' personal funding needs [42] Group 28 - Jinma Leisure announced a plan for a combined shareholding reduction of up to 4.83% [44] - The reduction is due to personal funding needs of the controlling shareholder and executives [44] Group 29 - *ST Zitian's stock may be terminated due to financial reporting issues [46] - The company is under regulatory scrutiny for failing to rectify its financial statements [46]

Group 1: Industry Overview - The oral implant industry in China consists of a comprehensive supply chain, including upstream raw material suppliers, equipment manufacturers, and software developers [1][4] - Upstream suppliers provide materials such as titanium and zirconia, while midstream includes implant manufacturers and distributors, and downstream consists of dental institutions offering implant services [1][4] Group 2: Regional Distribution - The distribution of companies within the oral implant industry is relatively dispersed, with Shandong province having a higher concentration of related enterprises [5] - Key companies in Shandong include Guocera Materials and Zhenghai Bio, while Guangdong has a concentration of upstream suppliers like Aierchuang and Dongfang Zirconium [5] Group 3: Representative Companies - Major companies in the oral implant sector include Tongce Medical, Aojing Medical, and Ruier Group, with varying revenue contributions from their implant services [9][10] - For instance, Yaboshi generated 816 million yuan from implant services, accounting for 51.75% of its total revenue [10] Group 4: Recent Developments - Yaboshi received an A-level rating in a comprehensive evaluation of dental institutions in Suzhou in April 2025 [12] - Tongce Medical acquired 80% of Hangzhou Haiyin Technology for 55.41 million yuan to enhance its dental product design and development capabilities [12] - Aojing Medical showcased its innovative dental products at the International Dental Exhibition in Cologne, Germany, receiving high praise from experts [12]

1、OssaNova™人工骨修复材料 注册证编号：2502543ĐKLH/BYT-HTTB 产品名称：人工骨修复材料 证件有效期：2025.07.16-永久有效 证券代码：688613 证券简称：奥精医疗 公告编号：2025-038 奥精医疗科技股份有限公司 自愿披露关于公司产品在越南获得注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奥精医疗科技股份有限公司（以下简称"公司"）于2024年12月向越南卫生部 递交了公司人工骨修复材料的注册申报资料。公司于近日收到越南卫生部通知，公 司人工骨修复材料获得批准。现将相关情况公告如下： 一、注册证内容 奥精医疗科技股份有限公司董事会 2025年7 月 22 日 产品分类：D类（高风险医疗器械） 二、医疗器械基本情况 1、OssaNova™人工骨修复材料 本次获得越南注册证的OssaNova™人工骨修复材料是基于奥精医疗具有完全自主 知识产权的体外仿生矿化技术研发和生产的一种仿生矿化胶原人工骨修复材料，在 组成成分和微观结构上均对人体天然骨组织高度仿生。产品用于口腔 ...

奥精医疗公告，公司于2024年12月向越南卫生部递交了人工骨修复材料的注册申报资料，近日收到通 知，该材料获得批准。OssaNova 人工骨修复材料是基于公司具有完全自主知识产权的体外仿生矿化技 术研发和生产的一种仿生矿化胶原人工骨修复材料。产品用于口腔科或整形外科无植骨禁忌的骨缺损修 复，植入体内后能够在引导骨再生的同时被新生骨组织爬行替代。本次公司产品在越南获得注册证，是 公司海外业务拓展的重要组成部分，将对公司产品在海外的销售起到一定的推动和促进作用。 ...

Core Insights - The Chinese dental beauty industry is experiencing rapid growth, driven by increasing consumer demand for oral health and aesthetics, with a market size expected to exceed 78.5 billion yuan by 2025 [1][16][25] - The industry is characterized by three main features: explosive demand from 718 million oral disease patients, innovation in supply with a 25% penetration rate of invisible orthodontics, and rapid market expansion with a CAGR of 15.9% from 2018 to 2023 [1][12][16] Industry Overview - Dental beauty focuses on improving the appearance, shape, and alignment of teeth through non-invasive or minimally invasive techniques, aiming to unify natural aesthetics and functionality [2] - The industry includes various segments such as teeth whitening, veneer restoration, crown restoration, orthodontics, and gum shaping [2] Development Drivers - **Consumer Upgrade and Demand Change**: The shift from essential treatment to aesthetic consumption is evident, with over 60% of Gen Z viewing teeth whitening as key to confidence [4][16] - **Technological Innovation**: Breakthroughs in materials science and digital technology are reshaping industry standards, with AI aesthetic design and 3D printing significantly enhancing service efficiency [6][25] - **Policy and Capital Synergy**: Government initiatives like "Healthy China 2030" and increased financing are facilitating industry growth and standardization [7][25] - **Silver Economy and Niche Market Rise**: The aging population is driving demand for dental aesthetics, with 35% of spending on implants and aesthetic restorations coming from those aged 50 and above [8][25] Industry Chain - The industry chain exhibits high collaboration and vertical integration, with upstream focusing on high-value consumables and digital equipment, while domestic brands are rapidly replacing foreign ones in the mid-range market [9][20] Market Size and Growth - The market size grew from 28.56 billion yuan in 2018 to 59.82 billion yuan in 2023, with a projected growth to over 78.5 billion yuan by 2025 [16][18] Competitive Landscape - The industry features a multi-tiered competition structure, with foreign brands dominating the high-end market and domestic brands rapidly expanding in the mid-range and low-end markets [20][22] - The top five brands in the implant sector hold nearly 70% market share, while the invisible orthodontics market is dominated by two major players [20][22] Future Trends - **Technological Integration**: The industry is moving towards full-cycle intelligent management, integrating AI, 3D printing, and biological materials [25][26] - **Market Layering and Downstream Expansion**: The competition is characterized by high-end precision, mid-range differentiation, and low-end accessibility, with community health stations expanding rapidly [27][28] - **Ecosystem Reconstruction and Regulatory Upgrades**: The industry is evolving towards a cross-sector integration of healthcare, technology, and consumer services, with increased regulatory oversight [28]

Summary of Key Points Core Viewpoint - Aojing Medical (688613) has shown a slight increase in stock price, reflecting ongoing adjustments in its fundraising projects and governance decisions [1]. Company Performance - As of July 11, 2025, Aojing Medical's stock closed at 18.31 yuan, up 0.22% from the previous week [1]. - The stock reached a weekly high of 18.77 yuan on July 7 and a low of 17.7 yuan on July 10 [1]. - The company's current total market capitalization is 2.509 billion yuan, ranking 113th out of 126 in the medical device sector and 4692nd out of 5149 in the overall A-share market [1]. Corporate Governance - Aojing Medical held its first extraordinary general meeting of 2025 on July 11, 2025, in Beijing, with 89 attendees representing 26,135,097 shares, accounting for 19.0755% of the voting rights [1]. - The meeting approved adjustments to certain fundraising project implementation subjects, locations, and sub-projects, with 98.7191% of votes in favor, 1.2186% against, and 0.0623% abstaining [1]. - The meeting was witnessed by lawyers from Beijing Zhonglun Law Firm, confirming that all procedures and results complied with relevant laws and regulations [1].

Core Viewpoint - The legal opinion letter confirms that the procedures for convening and holding the 2025 first extraordinary general meeting of shareholders of Aojing Medical Technology Co., Ltd. comply with relevant laws and regulations [1][5][6]. Group 1: Meeting Procedures - The company published the notice for the extraordinary general meeting on June 26, 2025, which included details such as meeting time, voting methods, and agenda items, with a notice period of 15 days before the meeting [2][3]. - The meeting was held on July 11, 2025, at a specified location, and was presided over by the company's chairman, Eric Gang Hu [3]. Group 2: Attendance and Qualifications - A total of 89 shareholders and authorized agents attended the meeting, holding 26,135,097 shares, which represents a significant portion of the voting rights as of the registration date [5][6]. - The qualifications of the attendees and the convenor of the meeting were verified to be in accordance with the relevant laws and the company's articles of association [5][6]. Group 3: Voting Procedures and Results - The voting process combined both on-site and online methods, with results being counted and announced immediately after the meeting [7]. - The meeting approved the agenda items as listed in the notice, and there were no objections raised regarding the voting results [7]. Group 4: Conclusion - The legal opinion concludes that all aspects of the meeting, including convening, attendance, and voting procedures, were conducted in compliance with applicable laws and regulations, rendering the results valid [5][7].